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Mesenchymal stem cells are short-lived
and do not migrate beyond the lungs after
intravenous infusion
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Mesenchymal stromal cells (MSCs) are
under investigation for clinical applica-
tion. Despite approval by the United
States Food and Drug Administration for
MSC use in pediatric steroid-refractory
acute GvHD after allogeneic hematopoi-
etic stem cell transplantation (Parekkadan
and Milwid, 2010) uncertainty about
the fate of MSCs after infusion remains
thus far. Clinical trials have provided
evidence for high response rates, efficacy,
and safety leading to mortality reduction
after MSC treatment of GvHD (Bernardo
et al., 2010). Recently de Girolamo et al.
(2012) have reviewed clinical observations
and critical aspects extensively. Systemic
immunomodulation following MSC treat-
ment has been demonstrated (Dander
et al., 2012; Zanotti et al., 2013), regard-
less of the many unresolved questions
including possible entrapment in the lungs
and liver, homing to sites of inflamma-
tion or trauma, and the relevance of
chimerism.
Recently, Eggenhofer et al. (2012) pre-
sented evidence in a mouse model that
cultured bone-marrow derived MSCs are
entrapped in the lungs after intravenous
infusion. These results confirm that, in
addition to a need for greater under-
standing of their functional and immuno-
logic characteristics, there is also a need
to investigate the migratory properties of
cultured MSCs in circulation prior to
clinical implementation. We congratulate
Eggenhofer et al. for their experimental
insights. Herein, we propose to summa-
rize some salient aspects of existing liter-
ature evidence and our own experience in
response to some comments and conclu-
sions made by the authors.
The present study supports the find-
ings from Fischer et al. (2009), who have
described a first-pass effect in the lung
capillaries for MSCs. These authors used
MSCs up to passage 4 and could demon-
strate that cells from a second bolus injec-
tion passed the lungs more efficiently. This
study elegantly could show a dependency
of MSCs and their ability to pass the lung
filter on size and surface antigens.
In rodent and swine transplant mod-
els, intravenous delivery of MSCs has been
shown to achieve long-term peripheral
blood chimerism. Some of these studies
(Kuo et al., 2009, 2011; Pan et al., 2010)
prove that MSCs survived for months or
long-term in the periphery without com-
plete entrapment in the pulmonary cap-
illary bed. However, they also confirmed
on histopathology that homing ofMSCs to
lungs does occur (Kuo et al., 2009).
In our own experiments, we inves-
tigated sites of vascular regeneration in
a critically perfused skin-flap model in
immunocompetent mice (C57BL/6) after
transplantation of fluorescent allogeneic
MSCs. Freshly isolated Lin−CD105+
bone-marrow derived MSCs (2×
105/animal in 100µm 0.9% NaCl via
tail vein injection), were infused via tail
vein injection. MSCs exhibited perivascu-
lar homing remote to the lungs and liver
as well as paracrine expression of growth
factors mediating vascular regeneration
in specific sites. We were able to visualize
MSCs in vivo by intravital fluorescence
microscopy and laser scanning confocal
microscopy and post mortem histologically
in the peripheral tissue (Schlosser et al.,
2012). Over time, cell numbers increased
but they did not change their morphology
(Figure 1). Yet, we could not differentiate
whether this was due to local proliferation
or further recruitment of MSCs in these
experiments.
Cultured MSCs may not be phenotyp-
ically distinguishable from fibroblasts and
may even share similar surface antigens or
differentiation potential (Hematti, 2012).
With regards to cultured fibroblasts, we
found that these cells induced lethal pul-
monary embolism if infused too quickly
(<1min; own unpublished data) but slow
IV injection was consistent with survival.
The findings by Eggenhofer et al. (2012)
of predominant lung entrapment explain
our observational findings of mortality.
However, in other studies, Schlosser et al.
(2012) reported that entrapped fibroblasts
exhibit regenerative effects over critically
perfused skin. These findings may indi-
rectly support conclusions of Eggenhofer
et al. that MSCs could mediate distant
effects via endocrine mechanisms.
In the past, it has been shown that
the duration and degree of cell expansion
and culture has a clear impact on MSC
morphology, differentiation, viability, and
migratory properties (Wagner et al., 2010).
Freshly isolatedMSCs show superior hom-
ing ability compared to expanded cells
(Rombouts and Ploemacher, 2003), which
might be due to their size (own unpub-
lished data; Fischer et al., 2009) as well
as unique homing factors. Importantly,
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FIGURE 1 | (A) Fluorescent MSC (yellow) after perivascular homing to critically ischemic skin. 3D reconstruction from Laser-Scanning Confocal Microscopy.
(B) Fluorescent MSCs (green) 14 days after tailvein injection and homing to critically ischemic skin. (Freshly isolated BM-MSC; tail vein injection).
MSCs not only undergo phenotypic
changes in culture and during passage
(size, morphology, and cell surface marker
expression) (Wagner et al., 2010; Hematti,
2012), but also lose capacity for func-
tional proliferation and differentiation
potential (Vacanti et al., 2005; Wagner
et al., 2010). In addition, their ability for
cytokine production is altered (Banfi et al.,
2002; Vacanti et al., 2005).
To avoid the first pass effect and con-
sequent pulmonary capillary entrapment
following MSC transplantation, Zonta
et al. (2010) suggest an arterial route
of access. They delivered MSCs to the
renal artery during kidney transplanta-
tion in rodents and reported favorable
recovery of kidney function as opposed
to the intravenous route. Arterial appli-
cation might thus enable direct deliv-
ery to the capillary bed of the graft
with reduced cell loss through entrapment
and consequent unwarranted systemic
effects.
Pulmonary and hepatic entrapment of
MSCs has been intensely debated and
studied for years. The study by Eggenhofer
et al. is the first to lucidly demonstrate
that cultured MSCs undergo significant
entrapment in the lung after intravenous
application. It still remains speculative: (1)
If the degree of this phenomenon varies
with the size of MSCs infused (based on
passage cycle or culture denominators);
(2) if there are long-term effects on lung
function due to the entrapped cells and;
(3) if the immunological efficacy of MSCs
could be improved through direct arterial
delivery to the graft or specific end organs.
There is some evidence that the loss of
cells through a first pass effect is indeed
lower with freshly isolated MSCs indicat-
ing a link to smaller cell size or possibly
related to enhanced viability and homing
capacity.
Taken together, studies comparing
effects of fresh isolated MSCs delivered
intra-arterially to the graft or in proxim-
ity to the end organ to those secondary
to passaged MSCs delivered via a periph-
eral intravenous route may be important
to define if indeed this is a technical or
procedural consideration essential for
incorporation into pre-clinical protocols
to optimize overall outcomes.
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